### Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

#### VERTEX PHARMACEUTICALS INC / MA

Form 4 July 17, 2013

## FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer

subject to Section 16. Form 4 or

Form 5 obligations may continue.

See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading

VERTEX PHARMACEUTICALS

(Print or Type Responses)

(Last)

(City)

1. Name and Address of Reporting Person \*

**MUELLER PETER** 

(First) (Middle)

(Zin)

C/O VERTEX **PHARMACEUTICALS** INCORPORATED, 130 WAVERLY

ST.

(Street)

(State)

4. If Amendment, Date Original

Filed(Month/Day/Year)

INC / MA [VRTX]

(Month/Day/Year)

07/15/2013

3. Date of Earliest Transaction

Symbol

6. Individual or Joint/Group Filing(Check Applicable Line)

Director

X\_ Officer (give title

Issuer

below)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

5. Relationship of Reporting Person(s) to

(Check all applicable)

EVP, Global R&D, CSO

10% Owner

Other (specify

**OMB APPROVAL** 

Estimated average

burden hours per

3235-0287

January 31,

2005

0.5

**OMB** 

Number:

Expires:

response...

CAMBRIDGE, MA 02139

(City)	(State)	(Zip) Tabl	e I - Non-I	<b>Derivative</b>	Secui	rities Acq	uired, Disposed o	of, or Beneficia	illy Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	ansaction Date 2A. Deemed th/Day/Year) Execution Date, if any (Month/Day/Year)		3. 4. Securities Acquired Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) (Instr. 8)			Beneficially Fo Owned (D	Ownership Form: Direct (D) or	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)	(Instr. 4)	
Common Stock	07/15/2013		M	7,500	A	\$ 18.93	151,900	D	
Common Stock	07/15/2013		S <u>(1)</u>	4,965	D	\$ 86.17 (2) (3)	146,935	D	
Common Stock	07/15/2013		S(1)	2,535	D	\$ 86.66 (3) (4)	144,400	D	

#### Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

	Persons who respond to the co	SEC 1474 (9-02)	
Reminder: Report on a separate line for each class of securities be	eneficially owned directly or indirectly.		Trust
Common Stock	5,568	I	Revocable Trust
Stock	4,770	I	401(k)

required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	\$ 18.93	07/15/2013		M	7,500	(5)	02/06/2018	Common Stock	7,500

# **Reporting Owners**

Reporting Owner Name / Address

Director 10% Owner Officer Other

MUELLER PETER C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY ST. CAMBRIDGE, MA 02139

EVP, Global R&D, CSO

8. l De Sec (In

## **Signatures**

Kenneth L. Horton, Attorney-In-Fact 07/17/2013

\*\*Signature of Reporting Person Date

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Reporting Owners 2

### Edgar Filing: VERTEX PHARMACEUTICALS INC / MA - Form 4

- (1) Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1.
- (2) Open market sales reported on this line occurred at a weighted average price of \$86.17 (range \$85.97 to \$86.35).
- (3) Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- (4) Open market sales reported on this line occurred at a weighted average price of \$86.66 (range \$86.38 to \$87.33).
- (5) Fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.